Skip to main content
. Author manuscript; available in PMC: 2017 Nov 30.
Published in final edited form as: Pharmacogenet Genomics. 2010 Nov;20(11):677–686. doi: 10.1097/FPC.0b013e32833f4f9b

Table 1.

Kinetics of CYP2D6 supported by POR variants, using EOMCC, dextromethorphan and bufuralol as substrates

EOMCC

POR Vmax ± SEM Km ± SEM Vmax / Km % WT
WT 3.8 ± 0.50 35.1 ± 2.11 0.111 100
Q153R 4.2 ± 0.04 29.6 ± 3.68 0.142 128*
A503V 2.6 ± 0.51 27.4 ± 3.40 0.095 85*
A287P NC NC NC NC
R457H NC NC NC NC
Dextromethorphan

POR Vmax ± SEM Km ± SEM Vmax / Km % WT
WT 9.3 ± 0.35 1.6 ± 0.67 5.813 100
Q153R 13.8 ± 2.27 1.2 ± 0.56 11.500 198*
A503V 6.5 ± 0.86 1.8 ± 0.34 3.611 62*
A287P 2.2 ± 0.41 1.4 ± 0.10 1.571 27*
R457H NC NC NC NC
Bufuralol

POR Vmax ± SEM Km ± SEM Vmax / Km % WT
WT 24.4 ± 1.82 5.0 ± 0.26 4.880 100
Q153R 35.0 ± 6.18 4.7 ± 0.43 7.447 153*
A503V 16.4 ± 2.29 6.4 ± 1.16 2.563 53*
A287P 8.7 ± 0.46 7.5 ± 0.86 1.160 24*
R457H NC NC NC NC

Note: The asterisk (*) indicates P < 0.05 for comparisons of WT and variant POR using ANOVA followed by post hoc test. NC = data could not be calculated.